Around 600,000 bottles of Ramipril, a common blood pressure medication, are being recalled due to potential contamination tied to an unregulated supplier in India. The recall, initiated by the FDA, includes 2.5 mg, 5 mg, and 10 mg doses distributed across the U.S.
Patients are advised to check their prescriptions and consult healthcare providers if affected. Although no adverse effects have been reported, the FDA labeled this a Class 2 recall, highlighting the need for caution.
Ramipril is vital for managing hypertension and preventing cardiovascular complications, making its recall a significant concern. This incident emphasizes the importance of rigorous quality control in the global pharmaceutical supply chain to ensure patient safety and trust.
